Advances in artificial intelligence (AI) and machine learning (ML) have shown significant promise is in the de novo generation of therapeutic...
Artificial intelligence (AI) and machine learning (ML) are playing increasingly significant roles in the field of drug discovery.
Phage display has become an invaluable tool for the discovery of novel therapeutic agents, including nanobodies.
NGS offers an approach for identifying and extracting variable domain heavy-chain (VHH) regions from camelid B-cells.
In the fight against infectious diseases, scientists are continually seeking to outsmart pathogens. One such strategy involves the use of nanobodies.
In the search for new therapies that can treat a wide variety of neurodegenerative diseases, scientists are exploring the potential of nanobodies.
An emerging therapeutic strategy to tackle cancer is nanobodies – small, single-domain antibody fragments derived from heavy-chain-only antibodies.
Nanobodies, also known as single-domain antibodies or VHHs, are small, highly stable, and specific antibody fragments.
ADCs are essentially a new class of drugs that combine the targeting properties of antibodies with the cell-killing ability of drugs.
The sunk cost fallacy can affect our decision making around LIMS, other software, and antibody discovery technology purchases.